Abstract
Purpose: Objectives of the study are to analyze the correlation between [ 68 Ga]DOTATATE positron emission tomography (PET)/X-ray computed tomography (CT) measurements and various biological characteristics of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), and to determine optimal cutoff value of SUVmax (standard uptake value) to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs). Procedures: Of the GEP-NEN cases (73 males, 53 females; age 18–77 years) with pathologically proven primary and/or metastatic lesions, 126 were studied. All of the short axes of lesions were larger than 0.5 cm in order to avoid the partial volume effect. Patients fasted for 6 h before the PET/CT scans. The dose of [ 68 Ga]DOTATATE was 100–200 MBq and the acquisition began at 1 h after injection. The lesion with the highest SUVmax in each patient was analyzed. Results: In the total sample, the sensitivity of [68Ga]DOTATATE was 69.05 %. The sensitivities were significantly different among G1, G2, and G3 groups (72.22 %, 91.53 %, and 40.82 %, respectively; p < 0.01). The SUVmax of the G3 group was lowest. We also found that the sensitivity and SUVmax were significantly higher (p < 0.05) in patients with pancreatic NENs (Pan-NENs) than in patients with gastrointestinal NENs (Gi-NENs) and unknown primary NENs (Up-NENs). A significant negative correlation between SUVmax and Ki-67 was found (r = − 0.429, p < 0.01). Using SUVmax to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs), the area under the ROC curve (AUC) was 0.771 and the cutoff value of SUVmax was 11.25 (sensitivity 79.2 %, specificity 65.3 %). However, Pan-NENs did not show any statistical significance results in correlation and ROC analysis. Conclusion: [ 68 Ga]DOTATATE PET/CT results showed a negative correlation with GEP-NEN cell proliferation and were complementary to Ki-67. Pan-NENs were different from Gi-NENs and Up-NENs when compared to somatostatin receptor expression.
| Original language | English (US) |
|---|---|
| Journal | Molecular Imaging and Biology |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Cell proliferation
- Neuroendocrine tumor
- PET/CT
- Somatostatin receptor
- [ Ga]DOTATATE
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Cite this
The Correlation Between [ 68 Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs . / Yu, Jiangyuan; Li, Nan; Li, Jie; Lu, Ming; Leal, Jeffrey Pettit; Tan, Huangying; Su, Hua; Fan, Yang; Zhang, Yan; Zhao, Wei; Zhu, Hua; Pomper, Martin Gilbert; Zhou, Yun; Yang, Zhi.
In: Molecular Imaging and Biology, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Correlation Between [ 68 Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs
AU - Yu, Jiangyuan
AU - Li, Nan
AU - Li, Jie
AU - Lu, Ming
AU - Leal, Jeffrey Pettit
AU - Tan, Huangying
AU - Su, Hua
AU - Fan, Yang
AU - Zhang, Yan
AU - Zhao, Wei
AU - Zhu, Hua
AU - Pomper, Martin Gilbert
AU - Zhou, Yun
AU - Yang, Zhi
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose: Objectives of the study are to analyze the correlation between [ 68 Ga]DOTATATE positron emission tomography (PET)/X-ray computed tomography (CT) measurements and various biological characteristics of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), and to determine optimal cutoff value of SUVmax (standard uptake value) to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs). Procedures: Of the GEP-NEN cases (73 males, 53 females; age 18–77 years) with pathologically proven primary and/or metastatic lesions, 126 were studied. All of the short axes of lesions were larger than 0.5 cm in order to avoid the partial volume effect. Patients fasted for 6 h before the PET/CT scans. The dose of [ 68 Ga]DOTATATE was 100–200 MBq and the acquisition began at 1 h after injection. The lesion with the highest SUVmax in each patient was analyzed. Results: In the total sample, the sensitivity of [68Ga]DOTATATE was 69.05 %. The sensitivities were significantly different among G1, G2, and G3 groups (72.22 %, 91.53 %, and 40.82 %, respectively; p < 0.01). The SUVmax of the G3 group was lowest. We also found that the sensitivity and SUVmax were significantly higher (p < 0.05) in patients with pancreatic NENs (Pan-NENs) than in patients with gastrointestinal NENs (Gi-NENs) and unknown primary NENs (Up-NENs). A significant negative correlation between SUVmax and Ki-67 was found (r = − 0.429, p < 0.01). Using SUVmax to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs), the area under the ROC curve (AUC) was 0.771 and the cutoff value of SUVmax was 11.25 (sensitivity 79.2 %, specificity 65.3 %). However, Pan-NENs did not show any statistical significance results in correlation and ROC analysis. Conclusion: [ 68 Ga]DOTATATE PET/CT results showed a negative correlation with GEP-NEN cell proliferation and were complementary to Ki-67. Pan-NENs were different from Gi-NENs and Up-NENs when compared to somatostatin receptor expression.
AB - Purpose: Objectives of the study are to analyze the correlation between [ 68 Ga]DOTATATE positron emission tomography (PET)/X-ray computed tomography (CT) measurements and various biological characteristics of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), and to determine optimal cutoff value of SUVmax (standard uptake value) to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs). Procedures: Of the GEP-NEN cases (73 males, 53 females; age 18–77 years) with pathologically proven primary and/or metastatic lesions, 126 were studied. All of the short axes of lesions were larger than 0.5 cm in order to avoid the partial volume effect. Patients fasted for 6 h before the PET/CT scans. The dose of [ 68 Ga]DOTATATE was 100–200 MBq and the acquisition began at 1 h after injection. The lesion with the highest SUVmax in each patient was analyzed. Results: In the total sample, the sensitivity of [68Ga]DOTATATE was 69.05 %. The sensitivities were significantly different among G1, G2, and G3 groups (72.22 %, 91.53 %, and 40.82 %, respectively; p < 0.01). The SUVmax of the G3 group was lowest. We also found that the sensitivity and SUVmax were significantly higher (p < 0.05) in patients with pancreatic NENs (Pan-NENs) than in patients with gastrointestinal NENs (Gi-NENs) and unknown primary NENs (Up-NENs). A significant negative correlation between SUVmax and Ki-67 was found (r = − 0.429, p < 0.01). Using SUVmax to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs), the area under the ROC curve (AUC) was 0.771 and the cutoff value of SUVmax was 11.25 (sensitivity 79.2 %, specificity 65.3 %). However, Pan-NENs did not show any statistical significance results in correlation and ROC analysis. Conclusion: [ 68 Ga]DOTATATE PET/CT results showed a negative correlation with GEP-NEN cell proliferation and were complementary to Ki-67. Pan-NENs were different from Gi-NENs and Up-NENs when compared to somatostatin receptor expression.
KW - Cell proliferation
KW - Neuroendocrine tumor
KW - PET/CT
KW - Somatostatin receptor
KW - [ Ga]DOTATATE
UR - http://www.scopus.com/inward/record.url?scp=85061968350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061968350&partnerID=8YFLogxK
U2 - 10.1007/s11307-019-01328-3
DO - 10.1007/s11307-019-01328-3
M3 - Article
C2 - 30796708
AN - SCOPUS:85061968350
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
SN - 1536-1632
ER -